Skip to main content

Drug Interactions between fenofibrate and fluvastatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

fluvastatin fenofibrate

Applies to: fluvastatin and fenofibrate

GENERALLY AVOID: Severe myopathy and rhabdomyolysis have been reported during concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives, especially gemfibrozil. Gemfibrozil has been reported to significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their active metabolites, including lovastatin, simvastatin, pravastatin, cerivastatin, and rosuvastatin (but not fluvastatin). High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. Other fibrates have not been shown to significantly affect the pharmacokinetics of HMG-CoA reductase inhibitors. However, the use of fibrates alone has also been associated with development of myopathy, thus a pharmacodynamic interaction could conceivably occur.

MANAGEMENT: Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of fibrates to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. If the combination is prescribed, a fibrate other than gemfibrozil may be preferable, along with lower initial dosages of the HMG-CoA reductase inhibitor. If gemfibrozil is used, rosuvastatin daily dosage should not exceed 10 mg. Lovastatin labeling recommends that the dosage not exceed 20 mg daily when prescribed with gemfibrozil or other fibrates. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.

References

  1. Pierce LR, Wysowski DK, Gross TP (1990) "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA, 264, p. 71-5
  2. Schwandt P (1979) "Drug interactions and side effects of hypolipidemic drugs." Int J Clin Pharmacol Biopharm, 17, p. 351-6
  3. (2002) "Product Information. Mevacor (lovastatin)." Merck & Co., Inc
  4. (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
  5. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  6. Lozada A, Dujovne CA (1994) "Drug interactions with fibric acids." Pharmacol Ther, 63, p. 163-76
  7. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE (1995) "Pharmacokinetics of the combination of fluvastatin and gemfibrozil." Am J Cardiol, 76, a80-3
  8. Abdul-Ghaffar NU, el-Sonbaty MR (1995) "Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy." J Clin Gastroenterol, 21, p. 340-1
  9. (2001) "Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
  11. (2001) "Product Information. Baycol (cerivastatin)." Bayer
  12. (2001) "Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical
  13. Duell PB, Connor WE, Illingworth DR (1998) "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol, 81, p. 368-9
  14. Tal A, Rajeshawari M, Isley W (1997) "Rhabdomyolysis associated with simvastatin-gemfibrozil therapy." South Med J, 90, p. 546-7
  15. Miller DB, Spence JD (1998) "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet, 34, p. 155-62
  16. Pogson GW, Kindred LH, Carper BG (1999) "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol, 83, p. 1146
  17. Murdock DK, Murdock AK, Murdock RW, Olson KJ, Frane AM, Kersten ME, Joyce DM, Gantner SE (1999) "Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders." Am Heart J, 138, p. 151-5
  18. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD (2000) "Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil." Am J Health Syst Pharm, 57, p. 461-4
  19. Rodriguez ML (2000) "Cerivastatin-induced rhabdomyolysis." Ann Intern Med, 132, p. 598
  20. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ (2000) "Plasma concentrations of active simvastatin acid are increased by gemfibrozil." Clin Pharmacol Ther, 68, p. 122-9
  21. Alexandridis G, Pappas GA, Elisaf MS (2000) "Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil." Am J Med, 109, p. 261-2
  22. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Lopez-Lirola A, Rodriguez-Rodriguez E, Santolaria-Fernandez F (2001) "Acute rhabdomyolysis associated with cerivastatin therapy." Arch Intern Med, 161, p. 893
  23. Mastroianni CM, dEttorre G, Forcina G, Lichtner M, Corpolongo A, Coletta S, Vullo V (2001) "Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia." AIDS, 15, p. 820-1
  24. Tomlinson B, Lan IW (2001) "Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: Is the interaction predictable?." Am J Med, 110, p. 669
  25. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ (2001) "Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate." Clin Pharmacol Ther, 69, p. 340-5
  26. Bruno-Joyce J, Dugas JM, MacCausland OE (2001) "Cerivastatin and gemfibrozil-associated rhabdomyolysis." Ann Pharmacother, 35, p. 1016-9
  27. Staffa JA, Chang J, Green L (2002) "Cerivastatin and reports of fatal rhabdomyolysis." N Engl J Med, 346, p. 539-40
  28. Roca B, Calvo B, Monferrer R (2002) "Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy." Ann Pharmacother, 36, p. 730-1
  29. Prueksaritanont T, Zhao JJ, Ma B, et al. (2002) "Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins." J Pharmacol Exp Ther, 301, p. 1042-51
  30. Williams D, Feely J (2002) "Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors." Clin Pharmacokinet, 41, p. 343-70
  31. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) "Gemfibrozil greatly increases plasma concentrations of cerivastatin." Clin Pharmacol Ther, 72, p. 685-91
  32. (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
  33. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ (2003) "Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance." Clin Pharmacol Ther, 73, p. 538-44
  34. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH (2002) "Effects of fibrates on metabolism of statins in human hepatocytes." Drug Metab Dispos, 30, p. 1280-7
  35. Fujino H, Shimada S, Yamada I, Hirano M, Tsunenari Y, Kojima J (2003) "Studies on the interaction between fibrates and statins using human hepatic microsomes." Arzneimittelforschung, 53, p. 701-7
  36. Schneck DW, Birmingham BK, Zalikowski JA, et al. (2004) "The effect of gemfibrozil on the pharmacokinetics of rosuvastatin." Clin Pharmacol Ther, 75, p. 455-63
  37. Jacob SS, Jacob S, Williams C, Deeg MA (2005) "Simvastatin, fenofibrate, and rhabdomyolysis." Diabetes Care, 28, p. 1258
  38. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ (2002) "Gemfibrozil inhibits CYP2C8-mediatd cerivastatin metabolism in human liver microsomes." Drug Metab Dispos, 30, p. 1352-6
  39. Ireland JH, Eggert CH, Arendt CJ, Williams AW (2005) "Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate." Ann Intern Med, 142, p. 949-50
  40. Davidson MH (2006) "Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions." Exp Opin Drug Saf, 5, p. 145-56
  41. Neuvonen PJ, Backman JT, Niemi M (2008) "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet, 47, p. 463-74
  42. Unal A, Torun E, Sipahioglu MH, et al. (2008) "Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients." Intern Med, 47, p. 1017-9
View all 42 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer